Therapeutic use of multilamellar liposomal prostaglandin formulations
US5925375A · kind A · utility
11Cited by
28References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 3, 1994 |
| Grant date | Jul 20, 1999 |
| Priority date | — |
| Expiry date | Nov 3, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S977/915
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides a multilamellar liposome containing an arachidonic acid metabolite, two or more lipid-containing bilayers and two or more aqueous compartments containing a release-inhibiting buffer. Preferred arachidonic acid metabolites are the prostaglandins, particularly PGE.sub.1. The liposomal formulations can be used to treat animals, particularly humans, for diseases, disorders or conditions which can be ameliorated by prostaglandins, e.g., disorders characterized by cellular activation and adhesion, inflammation and/or toxemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.